- Joined
- Jun 28, 2015
- Messages
- 26
- Reaction score
- 78
This trial has “tell me your an academic that can’t get a pharma sponsored trial without saying so.”
That’s fair. That could have omitted / randomized out, tooYou know this is a POS trial because they allow HR therapy in both arms, as if HR therapy is less toxic than radiation therapy.
I'm not an omission guy.
That being said, this is a different question. These women almost never recur. This isn't a 10% to 1% reduction that we are going to poo poo and say "let's skip RT". Her2Neu+ patients that pCR have an incredibly good outcome.
I think it is really hard to separate relevant trials like this versus PRIME II, DEBRA (maybe that's wrong acronym, but whatever other ****ty omission trial), etc. When 80+% of the research is trash, then even the good trials start smelling like
Imagine NRG trying to do a trial similar to this.That’s fair. That could have omitted / randomized out, too
Who are the radoncs involved in this trial? Just curious if they are cheering residency expansion.Result = inferior locoregional control with omission of radiation
Publication = The authors conclude that it is indicated to omit radiation. Furthermore we speculate that radiation omission in all cases of pCR (including TNBR) can be reasonably extrapolated.
ASTRO = We are good until 2030 baby!
I am all for omission, but then it is our responsibility to adjust resident numbers
Had to see these ones coming from a mile away right?
“Six years ago, a medical oncologist told me he had never seen a patient with HER2-positive breast cancer develop local recurrence. I set out to find patients who had recurrence in this setting. Approximately 2,000 patients later, I have not seen one, either."
Do we really know that? Do we have the data for this? All patient have received RT so far.I'm not an omission guy.
That being said, this is a different question. These women almost never recur. This isn't a 10% to 1% reduction that we are going to poo poo and say "let's skip RT". Her2Neu+ patients that pCR have an incredibly good outcome.
Hope that the old Tyler Durden adage holds up. Rock bottom etc.But you know that will never happen…so now what?
“Really” know, no. You have to look at data (from like in the link I posted above) where 0 out of 2000 women (most were irradiated, but even so if all were irradiated…) fail locally, we conditionally begin to know that RT is unnecessary. For many stage I nowadays we trot out the local control argument because OS advantage is a non starter. Now, when a non RT treatment chips away at RT’s LC primacy… les jeux sont fais. Translation: the game is up. (Ed Rooney, not great at French.)Do we really know that? Do we have the data for this? All patient have received RT so far.
Hope that the old Tyler Durden adage holds up. Rock bottom etc.
Agreed, given how hard we’ve been bent it’s easy to chalk everything up as such.I'm not an omission guy.
That being said, this is a different question. These women almost never recur. This isn't a 10% to 1% reduction that we are going to poo poo and say "let's skip RT". Her2Neu+ patients that pCR have an incredibly good outcome.
I think it is really hard to separate relevant trials like this versus PRIME II, DEBRA (maybe that's wrong acronym, but whatever other ****ty omission trial), etc. When 80+% of the research is trash, then even the good trials start smelling like it.
The phase III study NRG should be running instead.
20 years ago, the prevailing paradigm was that no drug could completely sterilize a solid tumor.All fair points.
Just saying, 20 years ago, we likely would not collectively be as down about this study.
The past and present make it hard to be excited about what we have to offer.
But wait! Another gender and race study in one of our journals! "ongoing efforts are needed ... "
20 years ago, the prevailing paradigm was that no drug could completely sterilize a solid tumor.
Where are our best evidences and examples of this nowadays. Breast. Lung. Colorectal. Lymphomas (“semisolid” tumor I guess). Maybe the majority of discovered prostate tumors never need sterilization in the first place per the news this week. Maybe first hints in pancreatic (thanks COVID).20 years ago, the prevailing paradigm was that no drug could completely sterilize a solid tumor.
We will see what studies show, but we may be pleasantly surprised like dose de-escalation for p16 positive hn cancer.
"unless the candidate really really wants to go into radonc, then, yeah, its all good bro"I am all for omission, but then it is our responsibility to adjust resident numbers
Wouldn’t surprise me if it did. There are some big surgical and rad onc names on that author list. Accrual will be hardDo you know if this is progressing to a phase III in a cooperative group?